Abeona Therapeutics Inc. cash flow to debt ratio of -305.70% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Abeona Therapeutics Inc.'s free cash flow has decreased 44.20% from $-58.46M last year to $-84.30M, signaling decreasing performance

Abeona Therapeutics Inc.'s debt to equity ratio is 0.16, which means that the company's assets are healthy financed, signaling financial stability.

Abeona Therapeutics Inc.'s debt has decreased relative to shareholder equity from 0.52 last year to 0.16 today, signaling strengthened financials

Abeona Therapeutics Inc. has a net cash position, so leverage is healthy.

Abeona Therapeutics Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Abeona Therapeutics Inc. has insufficient data to evaluate this check.

Abeona Therapeutics Inc.'s short-term assets of $204.91M exceed its short-term liabilities of $29.57M

Abeona Therapeutics Inc.'s return on assets of 33.32% is higher than the 5.00% threshold, indicating efficient asset utilization

Abeona Therapeutics Inc.'s return on equity of 41.40%, is higher than 15.00%, indicating good performance

Abeona Therapeutics Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Abeona Therapeutics Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

Abeona Therapeutics Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Abeona Therapeutics Inc. has negative free cash flow, indicating cash burn

Abeona Therapeutics Inc.'s yearly earnings has increased -211.69% since last year from $-63.73M to $71.18M, signaling increasing performance

Abeona Therapeutics Inc.'s yearly revenue has increased % since last year from $0.00 to $5.82M, signaling increasing performance

ROIC -50.87% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Abeona Therapeutics Inc.'s 3-year revenue CAGR of 60.26% is positive, indicating growing revenue over the past 3 years

Abeona Therapeutics Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Abeona Therapeutics Inc. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

Abeona Therapeutics Inc. has insufficient data to evaluate this check.

Abeona Therapeutics Inc. has an earnings yield of 15.68%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Abeona Therapeutics Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Abeona Therapeutics Inc. has an EV/EBITDA ratio of 3.29x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Abeona Therapeutics Inc. is overvalued relative to its fair value price of -13.39 based on Earnings Fair Value model

Abeona Therapeutics Inc. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

Abeona Therapeutics Inc. has a price-to-book ratio of 2.91x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Abeona Therapeutics Inc. has a price-to-sales ratio of 29.01x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue